Ribo’s RBD1119 Moves Into Phase 2 Development for Coronary Artery Disease
SUZHOU, China, May 29, 2026 Suzhou Ribo Life Science and Ribocure Pharmaceuticals (collectively “Ribo”) have announced the submission of...
antibody-drug conjugate
Advertisement
Gilead Expands Oncology Portfolio With Tubulis Deal
Foster City, California, USA – May 22, 2026 Gilead Sciences, Inc. announced the successful completion of its acquisition of...
Kelun-Biotech Highlights Major NSCLC Data at ASCO 2026
CHENGDU, China, 21 May 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that two registrational studies involving its lead oncology...
Iza-bren Meets Dual Endpoints in Phase III TNBC
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
Day One Biopharma Acquires Mersana to Advance ADC Pipeline
BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...
Advertisements
Tubulis Secures €344 M Series C to Accelerate ADC Clinical Growth
Munich, Germany, October 30, 2025 — Tubulis GmbH announced the successful second and final closing of its Series C...
Tagworks Advances TGW101 in Phase 1 Trial for Solid Tumors
NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing...
Advertisement
